Conference Coverage (AACR)

Over-expressed Oncogene Potential Anti-Cancer Target

Published in Gene Therapy Weekly, April 21st, 1997

Preliminary data from a Phase I clinical gene therapy trial of HER-2/neu over-expressing ovarian or breast cancer were presented at the American Association for Cancer Researchers Conference (AACR) held April 12-16, 1997, in San Diego, California.

Speaking at the conference, Mien-Chie Hung of the University of Texas M.D. Anderson Cancer Center, Houston, Texas, explained the background material which led to this landmark clinical trial and speculated on future developments.

HER-2/neu, which is also named c-erbB-2, is an oncogene known to be over-expressed in numerous human cancers, including breast, ovarian, lung, gastric, and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-04-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry